Methods of assessment of urogenital atrophy and the implication of these in estimated prevalence rates: A review of the literature.
Briggs P Burton R Mosely C Sharp I Mercy F Delanerolle G Hapangama DK
Briggs P
Burton R
Mosely C
Sharp I
Mercy F
Delanerolle G
Hapangama DK
Abstract
Urogenital atrophy is caused by lack of estrogen, most commonly due to the menopause. Symptoms frequently experienced include vaginal dryness, itching, burning, sexual difficulties and urinary problems, all of which can have a significant adverse effect on quality of life. Effective treatments are available for women with a confirmed diagnosis. The aim of this review is to determine whether a consistent diagnostic intervention exists, to support an accurate indication of prevalence. Materials and Methods: This study is a review of the literature. A total of 1469 papers were identified on an initial search, including randomised controlled trials, cross sectional and cohort studies. By adoption of a systematic process, the number of papers in the final review was eight.There is inconsistent use of available assessment methods to diagnose urogenital atrophy in symptomatic women. There are no validated clinical assessment tools. Absence of a defined intervention with which to confirm a diagnosis of urogenital atrophy, based on symptoms, influences research outcomes, but more importantly affects access to an accurate diagnosis and treatment, for affected women. This would ideally take place in a primary care setting.
MIDER Authors
Citations
Altmetric:
Date
2023-09.01
Type
Article
Subject
Gynaecology
Collections
Citation
Briggs P, Burton R, Mosely C, Sharp I, Mercy F, Delanerolle G, Hapangama DK. Methods of assessment of urogenital atrophy and the implication of these in estimated prevalence rates: A review of the literature. Post Reprod Health. 2023 Sep;29(3):135-142. doi: 10.1177/20533691231199803. PMID: 37707431.
Journal / Source Title
Post Reproductive Health
DOI
10.1177/20533691231199803
PMID
37707431
Publisher
Sage